Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
ESMO 2023 – GSK sets up Pfizer battle in B7-H4
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
